Journal
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 18, Issue 6, Pages 861-877Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/108497803322702833
Keywords
Auger-electron emitters; radiobiologic effects; 5-radioiodo-2 '-deoxyuridine; iodine-125; iodine-123; tumor targeting; tumor therapy; Auger electrons; radionuclide therapy; animal models; patient studies; biochemical modulation; tumors
Ask authors/readers for more resources
Auger-electron emitters represent an attractive alternative to beta-particle emitters for cancer therapy if they can be placed intracellularly, especially in close proximity to (or within) nuclear DNA. Based on investigations in animal tumor models, including those for ovarian cancer, bladder cancer, and brain and spinal cord tumors, in which the thymidine analog 5-radioiodo-2'-deoxyuridine (*IUdR) has been shown to be therapeutically efficacious, it is hypothesized that iodine-125 and other Auger-electron-emitting radionuclides might be valuable in the treatment of certain malignant diseases, assuming that uptake of the radiopharmaceutical by tumor cells exceeds that by normal dividing cells. Preliminary patient studies have shown that this requirement can be met partially by the locoregional administration of the radiopharmaceutical and metabolic modulation of its uptake by tumor cells. Investigators continue to seek molecules that can carry Auger-electron emitters to nuclear DNA, especially those radionuclides with higher Auger-electron yields and varying half-lives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available